Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms
Amgen Inc.’s stock AMGN tumbled 7.8% in early trade Tuesday, after the company said a mid-stage trial of its weight-loss ...
Amgen shows 20% weight loss in once-monthly injectable MariTide
Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn ...
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% of their body weight in a mid-stage ...
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.
Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen drug leads to up to 20% weight loss in trial
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
New Drug Causes 20 Percent Weigh Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen share price plummets despite Phase II weight loss success
Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...
The Express Tribune1 小时
Amgen's experimental injection leads to 20% average weight loss in key trial
MariTide was administered monthly or less frequently, which could provide an edge over the popular weekly injections ...
Amgen weight loss data ‘underwhelms,’ says Deutsche Bank
MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...